191 related articles for article (PubMed ID: 38071082)
21. Donor-Derived CD7 CAR-T Therapy Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Acute T-Lymphocytic Leukemia Associated With Hepatitis B: A Case Report.
Li Z; Meng F; Li J; Wu T
Front Immunol; 2022; 13():931452. PubMed ID: 35903089
[TBL] [Abstract][Full Text] [Related]
22. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.
Porter DL; Hwang WT; Frey NV; Lacey SF; Shaw PA; Loren AW; Bagg A; Marcucci KT; Shen A; Gonzalez V; Ambrose D; Grupp SA; Chew A; Zheng Z; Milone MC; Levine BL; Melenhorst JJ; June CH
Sci Transl Med; 2015 Sep; 7(303):303ra139. PubMed ID: 26333935
[TBL] [Abstract][Full Text] [Related]
23. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.
Geethakumari PR; Awan F
Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors.
Kharfan-Dabaja MA; Wierda WG; Cooper LJ
Leukemia; 2014 Mar; 28(3):507-17. PubMed ID: 24157582
[TBL] [Abstract][Full Text] [Related]
25. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
Front Immunol; 2021; 12():755549. PubMed ID: 34777367
[TBL] [Abstract][Full Text] [Related]
26. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
Hallek M
Am J Hematol; 2019 Nov; 94(11):1266-1287. PubMed ID: 31364186
[TBL] [Abstract][Full Text] [Related]
27. Chronic Lymphocytic Leukemia: Chemotherapy Free and Other Novel Therapies Including CAR T.
Wiedmeier-Nutor J; Leis J
Curr Treat Options Oncol; 2022 Jun; 23(6):904-919. PubMed ID: 35435617
[TBL] [Abstract][Full Text] [Related]
28. Targeted therapy in chronic lymphocytic leukemia: past, present, and future.
Danilov AV
Clin Ther; 2013 Sep; 35(9):1258-70. PubMed ID: 24054703
[TBL] [Abstract][Full Text] [Related]
29. Advances in the diagnosis and treatment of chronic lymphocytic leukemia.
Abbott BL
Clin Adv Hematol Oncol; 2004 Jul; 2(7):448-54. PubMed ID: 16163221
[TBL] [Abstract][Full Text] [Related]
30. [Ibrutinib combined with CAR-T cells in the treatment of del (17p) chronic lymphocytic leukemia with BCL-2 inhibitor resistance: a case report and literature review].
Gong JJ; Yin QS; Li MJ; Ai H; Wang Q; Chen L; Wei XD; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):750-754. PubMed ID: 31648477
[No Abstract] [Full Text] [Related]
31. Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies.
Rainone M; Siddiqi T
Curr Hematol Malig Rep; 2022 Feb; 17(1):39-45. PubMed ID: 35028825
[TBL] [Abstract][Full Text] [Related]
32. Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia.
Shustik C; Bence-Bruckler I; Delage R; Owen CJ; Toze CL; Coutre S
Ann Hematol; 2017 Jul; 96(7):1185-1196. PubMed ID: 28389687
[TBL] [Abstract][Full Text] [Related]
33. Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies.
ten Hacken E; Burger JA
Pharmacol Ther; 2014 Dec; 144(3):338-48. PubMed ID: 25050922
[TBL] [Abstract][Full Text] [Related]
34. Accelerating chimeric antigen receptor therapy in chronic lymphocytic leukemia: The development and challenges of chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia.
Bair SM; Porter DL
Am J Hematol; 2019 May; 94(S1):S10-S17. PubMed ID: 30861173
[TBL] [Abstract][Full Text] [Related]
35. Is There a Role for Cellular Therapy in Chronic Lymphocytic Leukemia?
Dreger P
Cancer J; 2021 Jul-Aug 01; 27(4):297-305. PubMed ID: 34398556
[TBL] [Abstract][Full Text] [Related]
36. Chronic lymphocytic leukemia therapy: new targeted therapies on the way.
Vitale C; Burger JA
Expert Opin Pharmacother; 2016 Jun; 17(8):1077-89. PubMed ID: 26988407
[TBL] [Abstract][Full Text] [Related]
37. Chimeric Antigen Receptor T-cell Therapy for Chronic Lymphocytic Leukemia: What is the supporting evidence so far?
Mohty R; Alotaibi S; Gadd M; Luo Y; Parrondo R; Qin H; Kharfan-Dabaja MA
Clin Hematol Int; 2023; 5(4):33-46. PubMed ID: 38817957
[TBL] [Abstract][Full Text] [Related]
38. Chronic lymphocytic leukemia (CLL)-Then and now.
Rai KR; Jain P
Am J Hematol; 2016 Mar; 91(3):330-40. PubMed ID: 26690614
[TBL] [Abstract][Full Text] [Related]
39. Real-world management of targeted therapies in chronic lymphocytic leukemia.
Weis TM; Gutierrez J; Kabel CC; King AC; Daley RJ; Stump SE
J Oncol Pharm Pract; 2022 Sep; 28(6):1411-1433. PubMed ID: 35350909
[TBL] [Abstract][Full Text] [Related]
40. Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape.
Iovino L; Shadman M
Curr Treat Options Oncol; 2020 Mar; 21(4):24. PubMed ID: 32170458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]